This study aims to evaluate the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. Participants will be randomly assigned, in a double-blind manner, to receive either the peptide hair serum or topical minoxidil. The primary objective is to assess improvement in hair growth over the study period, including changes in hair density and hair thickness. Secondary outcomes will include safety and tolerability assessments. The findings of this study may provide evidence supporting an alternative treatment option for patients with androgenetic alopecia.
Male or female participants aged ≥18 years.
Diagnosed with androgenetic alopecia (AGA): Norwood-Hamilton classification III-V in males or Ludwig classification I-II in females.
Able to read and write for completion of study questionnaires (e.g., Patient Global Assessment, Hair Growth Questionnaire).
Willing to comply with study procedures, including maintaining consistent hair color and hairstyle throughout the study.
Presence of unstable or uncontrolled systemic diseases that may affect hair growth or loss within 6 months prior to screening (e.g., liver, renal, thyroid, cardiovascular, neurological diseases, diabetes, anemia).
History of malignancy within the past 5 years, except adequately treated basal cell carcinoma or squamous cell carcinoma.
Psychiatric disorders or other conditions that may affect participant safety or compliance.
Pregnant or breastfeeding women.
Parallel
Veneze peptide hair serum
Other interventionParticipants will apply the VENEZE peptide factor hair serum to the affected scalp areas twice daily for 24 weeks according to the study protocol
Topical minoxidil
DrugTopical minoxidil solution applied to the scalp according to the study protocol for the treatment of androgenetic alopecia.
Change in hair density from baseline
Change from baseline in hair count within approximately 1 cm² target area at the vertex scalp, measured using standardized macrophotographic techniques at Weeks 12 and 24.
Change in hair diameter and terminal hair count from baseline
Change from baseline in hair diameter and the number of terminal hairs within approximately 1 cm² target area at the vertex scalp, measured using standardized macrophotographic techniques at Weeks 12 and 24.
Investigator Global Aesthetic Improvement Scale
Investigator assessment of treatment response using the Global Aesthetic Improvement Scale at the vertex and frontal scalp regions at baseline, week 12, and week 24.
Change in androgenetic alopecia severity
Change in AGA severity based on Norwood-Hamilton classification in males and Ludwig classification in females at baseline, week 12, and week 24.
Patient Global Assessment of hair growth
Change in patient-reported hair growth and satisfaction assessed using Patient Global Assessment (PGA) and Hair Growth Questionnaire scores at baseline, week 12, and week 24.
Click on the lead sponsor to view all of their trials.
Institute of Dermatology, Thailand
Lead sponsor
MEDEZE Cosmeceutical Company Limited
Collaborator
